Compare · BIIB vs MGX
BIIB vs MGX
Side-by-side comparison of Biogen Inc. (BIIB) and Metagenomi Therapeutics Inc. (MGX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BIIB and MGX operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- BIIB is the larger of the two at $28.15B, about 522.9x MGX ($53.8M).
- Over the past year, BIIB is up 62.7% and MGX is down 0.7% - BIIB leads by 63.4 points.
- BIIB has been more active in the news (14 items in the past 4 weeks vs 3 for MGX).
- BIIB has more recent analyst coverage (25 ratings vs 8 for MGX).
- Company
- Biogen Inc.
- Metagenomi Therapeutics Inc.
- Price
- $190.74+0.84%
- $1.44+2.86%
- Market cap
- $28.15B
- $53.8M
- 1M return
- +8.71%
- +5.49%
- 1Y return
- +62.75%
- -0.69%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2024
- News (4w)
- 14
- 3
- Recent ratings
- 25
- 8
Biogen Inc.
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB111 and BIIB112 to treat ophthalmology related diseases; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and TMS-007 to treat acute neurology; BIIB074 and BIIB095 for neuropathic pain; and SB11 and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Bristol-Myers Squibb Company; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Ginkgo Bioworks; Capsigen Inc.; and Mirimus, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Latest BIIB
- Amendment: SEC Form SCHEDULE 13G/A filed by Biogen Inc.
- Head of Corporate Development Keeney Adam converted options into 939 shares and covered exercise/tax liability with 455 shares, increasing direct ownership by 8% to 6,365 units (SEC Form 4)
- Jeito Capital Bolsters Its Leadership Team With the Appointment of Elaine Caughey, MBA, as Partner, Business Development and Investor Relations, and Sarah Shackelton, MPA, as Partner, Talent
- Stoke Therapeutics to Host Webcast and Conference Call to Discuss First Quarter 2026 Business and Financial Updates
- SEC Form 10-Q filed by Biogen Inc.
- Biogen Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SEC Form DEFA14A filed by Biogen Inc.
- SEC Form DEF 14A filed by Biogen Inc.
- FDA Approval for ZURZUVAE issued to BIOGEN INC
- Biogen upgraded by UBS with a new price target
Latest MGX
- SEC Form DEFA14A filed by Metagenomi Therapeutics Inc.
- SEC Form DEF 14A filed by Metagenomi Therapeutics Inc.
- Metagenomi Therapeutics, Inc. Announces Publication in Nature Structural & Molecular Biology Highlighting Proprietary Compact CRISPR Nuclease with Enhanced Genome Editing Efficiency
- SEC Form 4 filed by Irish Jian
- SEC Form 4 filed by Wein Matthew
- SEC Form 4 filed by Wapnick Pamela
- Chief Financial Officer Wapnick Pamela sold $2,530 worth of shares (1,581 units at $1.60), decreasing direct ownership by 0.84% to 187,375 units (SEC Form 4)
- Officer Wein Matthew sold $771 worth of shares (482 units at $1.60), decreasing direct ownership by 0.42% to 114,549 units (SEC Form 4)
- Chief Executive Officer Irish Jian gifted 228,462 shares and sold $2,571 worth of shares (1,607 units at $1.60), decreasing direct ownership by 41% to 333,770 units (SEC Form 4)
- SEC Form S-8 filed by Metagenomi Therapeutics Inc.